1372616-29-9

Basic information

• Product Name: 1-(benzyloxy)-3-(4-bromobutoxy)-2-nitrobenzene
• Synonyms: 1-(benzyloxy)-3-(4-bromobutoxy)-2-nitrobenzene
• CAS NO: 1372616-29-9
• Molecular Weight: 380.238
• Mol File: 1372616-29-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(benzyloxy)-3-(4-bromobutoxy)-2-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(benzyloxy)-3-(4-bromobutoxy)-2-nitrobenzene(1372616-29-9)
• EPA Substance Registry System: 1-(benzyloxy)-3-(4-bromobutoxy)-2-nitrobenzene(1372616-29-9)

Safety Data

• Hazardous Substances Data: 1372616-29-9(Hazardous Substances Data)

Upstream product

• 110-52-1 1,4-dibromo-butane 
• 213685-59-7 2-nitroresorcinol monobenzyl ether 
• 601-89-8 2-nitroresorcinol 
• 62000-10-6 (((2-nitro-1,3-phenylene)bis(oxy))bis(methylene))dibenzene 
• 100-39-0 benzyl bromide 

Downstream Products

• 1372616-30-2 1-(2-(1H-imidazol-1-yl ) ethyl)-4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazine 
• 1372616-32-4 3-(4-(4-(2-(1H-imidazol-1-yl)ethyl)piperazin-1-yl)butoxy)-2-aminophenol 
• 1372616-35-7 1-(4-(4-(2-amino-3-hydroxyphenoxy)butyl)piperazin-1-yl)-2-(1H-imidazol-1-yl)ethanone 
• 1386274-53-8 C₂HF₃O₂*C₂₁H₂₇N₃O₄ 
• 1372616-31-3 1-(4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazin-1-yl)-2-(1H-imidazol-1-yl)ethanone 
• 1372616-33-5 tert-butyl 4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazine-1-carboxylate 
• 1442655-89-1 N-(4-(3-benzyloxy-2-nitrophenoxy)butyl)-5-(dimethylamino)-N-methylnaphthalene-1-sulfonamide 
• 1442655-90-4 N-(4-(2-amino-3-hydroxyphenoxy)butyl)-5-(dimethylamino)-N-methylnaphthalene-1-sulfonamide 
• 1442655-88-0 4-(3-benzyloxy-2-nitrophenoxy)-N-methylbutan-1-amine 

Relevant articles and documents

ANTIMICROBIAL COMPOUNDS

Provided herein is technology relating to antimicrobial compounds and particularly, but not exclusively, to analogs of rifalazil having increased inhibition of RNA polymerase and decreased induction of human cy-tochrome P450. The compounds have an increased affinity for a bacterial RNA polymerase (e.g., a MTB RNA polymerase) and a decreased affinity for a human pregnane X receptor. Thus, in some embodiments, the steric clash of A or R with residues in the binding pocket of the human pregnane X receptor reduces an affinity of the compound for the human pregnane X receptor. Consequently, in some embodiments the steric clash thus reduces the induction (e.g., an activity) of a cytochrome P450 and/or other related proteins.